Omega Therapeutics Inc (OMGA)

Oct 15, 2024, 8:00 AM EDT - 4 months ago

Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings

Sep 17, 2024, 7:00 AM EDT - 5 months ago

Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications

Aug 14, 2024, 7:00 AM EDT - 6 months ago

Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research

Aug 6, 2024, 7:00 AM EDT - 7 months ago

Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Jun 24, 2024, 7:00 AM EDT - 8 months ago

Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors

May 30, 2024, 7:00 AM EDT - 9 months ago

Omega Therapeutics To Participate In Two Upcoming Investor Conferences

May 29, 2024, 7:00 AM EDT - 9 months ago

Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer

May 8, 2024, 7:00 AM EDT - 10 months ago

Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers

May 6, 2024, 7:00 AM EDT - 10 months ago

Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

Apr 23, 2024, 7:00 AM EDT - 10 months ago

Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting

Apr 9, 2024, 7:00 AM EDT - 11 months ago

Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control

Mar 31, 2024, 6:22 AM EDT - 11 months ago

Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'

NVO

Mar 28, 2024, 9:15 AM EDT - 11 months ago

Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update

Mar 6, 2024, 7:00 AM EST - 1 year ago

Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024

Jan 16, 2024, 2:10 PM EST - 1 year ago

Omega Therapeutics: The Next Weight Loss Drug Runner

Jan 4, 2024, 5:59 AM EST - 1 year ago

Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases

Jan 2, 2024, 4:05 PM EST - 1 year ago

Omega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 4, 2023, 4:00 PM EST - 1 year ago

Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Nov 20, 2023, 4:00 PM EST - 1 year ago

Omega Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference

Nov 13, 2023, 7:00 AM EST - 1 year ago

Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis

Nov 9, 2023, 7:00 AM EST - 1 year ago

Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Nov 7, 2023, 4:00 PM EST - 1 year ago

Omega Therapeutics to Participate in The Jefferies London Healthcare Conference

Oct 31, 2023, 7:00 AM EDT - 1 year ago

Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller

Oct 16, 2023, 7:00 AM EDT - 1 year ago

Omega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC

Oct 11, 2023, 4:00 PM EDT - 1 year ago

Omega Therapeutics Announces Two Poster Presentations on Liver Inflammation and Fibrosis at AASLD's The Liver Meeting® 2023

Oct 6, 2023, 8:26 AM EDT - 1 year ago

Top 4 Health Care Stocks That Are Preparing To Pump This Quarter - Omega Therapeutics (NASDAQ:OMGA), Cutera (NASDAQ:CUTR)

CUTR RVMD VNRX

Oct 4, 2023, 4:00 PM EDT - 1 year ago

Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 26, 2023, 7:00 AM EDT - 1 year ago

Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial

Sep 25, 2023, 4:00 PM EDT - 1 year ago

Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26

Sep 21, 2023, 4:00 PM EDT - 1 year ago

Omega Therapeutics to Participate in Two Upcoming Investor Conferences

Sep 11, 2023, 6:30 AM EDT - 1 year ago

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

DNLI FHTX MCRB MRNA SANA

Aug 29, 2023, 7:00 AM EDT - 1 year ago

Omega Therapeutics Announces Updates to its Board of Directors

Aug 3, 2023, 4:00 PM EDT - 1 year ago

Omega Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Aug 1, 2023, 4:29 PM EDT - 1 year ago

Omega Therapeutics: Working In Epigenetic Anti-Cancer Programs

Jul 12, 2023, 7:00 AM EDT - 1 year ago

Omega Therapeutics Appoints Chris Schade to its Board of Directors

Jun 21, 2023, 6:00 AM EDT - 1 year ago

Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs

DNLI FHTX MCRB MRNA SANA

May 31, 2023, 8:30 AM EDT - 1 year ago

Ashvattha Therapeutics Expands Leadership Team with Appointment of Paul E. Cayer as Chief Financial Officer and Mahesh Karande to the Board of Directors

May 31, 2023, 7:00 AM EDT - 1 year ago

Omega Therapeutics Presents New Preclinical Data Demonstrating the Potential of Omega Epigenomic Controllers™ to Synergize with Immunotherapies at the ASCO 2023 Annual Meeting

May 4, 2023, 7:00 AM EDT - 1 year ago

Omega Therapeutics Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

Apr 27, 2023, 7:00 AM EDT - 1 year ago

Omega Therapeutics to Present New Preclinical Data at the American Society of Clinical Oncology 2023 Annual Meeting

Mar 30, 2023, 7:00 AM EDT - 2 years ago

Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma

Mar 1, 2023, 7:00 AM EST - 2 years ago

Omega Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Feb 23, 2023, 7:00 AM EST - 2 years ago

Omega Therapeutics Announces $40 Million Registered Direct Offering of Common Stock

Jan 17, 2023, 7:00 AM EST - 2 years ago

Omega Therapeutics to Present Trial-in-Progress Poster for Phase 1/2 MYCHELANGELO™ I Study at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Dec 8, 2022, 8:00 AM EST - 2 years ago

KSQ Appoints Mahesh Karande to its Board of Directors

Nov 17, 2022, 7:00 AM EST - 2 years ago

Omega Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference

Nov 15, 2022, 7:00 AM EST - 2 years ago

Omega Therapeutics Named One of BioSpace's 2023 Best Places to Work

Nov 8, 2022, 7:00 AM EST - 2 years ago

Omega Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Nov 3, 2022, 7:00 AM EDT - 2 years ago

Omega Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 2, 2022, 7:00 AM EDT - 2 years ago

Omega Therapeutics Receives Orphan Drug Designation for OTX-2002 for the Treatment of Hepatocellular Carcinoma